Target:RERG
Gene Name:RERG
Protein Name:Ras-related and estrogen-regulated growth inhibitor
Human Gene Id:85004
Human Swiss Prot No:Q96A58
Mouse Gene Id:232441
Mouse Swiss Prot No:Q8R367
Immunogen:Synthesized peptide derived from RERG . at AA range: 70-150
Specificity:RERG Polyclonal Antibody detects endogenous levels of RERG protein.
Formulation:Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source:Polyclonal, Rabbit,IgG
Dilution:IHC 1:100 - 1:300. ELISA: 1:5000.. IF 1:50-200
Purification:The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration:1 mg/ml
Storage Stability:-15°C to -25°C/1 year(Do not lower than -25°C)
Other Name:RERG;Ras-related and estrogen-regulated growth inhibitor
Molecular Weight(Da):23kD
Background: RERG, a member of the RAS superfamily of GTPases, inhibits cell proliferation and tumor formation (Finlin et al., 2001 [PubMed 11533059]).[supplied by OMIM, Mar 2009],
Function:disease:Loss of RERG expression may contribute to tumorigenesis in breast. RERG expression is decreased or lost in a significant proportion of primary breast tumors with poor clinical prognosis. High expression of RERG correlates with long relapse-free survival times.,function:Binds GDP/GTP and possesses intrinsic GTPase activity. Has higher affinity for GDP than for GTP. In cell lines overexpression leads to a reduction in the rate of proliferation, colony formation and in tumorigenic potential.,induction:Up-regulated by estradiol. Down-regulated by tamoxifen.,similarity:Belongs to the small GTPase superfamily. Ras family.,tissue specificity:Detected in heart, brain, placenta, lung, liver, skin, kidney and pancreas. Detected in estrogen receptor-positive breast-derived cell lines, but not in estrogen receptor-negative cell lines.,
Subcellular Location:Cytoplasm .
Expression:Detected in heart, brain, placenta, lung, liver, skin, kidney and pancreas. Detected in estrogen receptor-positive breast-derived cell lines, but not in estrogen receptor-negative cell lines. Expression is decreased or lost in a significant proportion of primary breast tumors with poor clinical prognosis.